Brief: Surface Oncology Announces First Patient Dosed In A Phase 1/2 Study Evaluating SRF114
05/01/2023 12:35
Jan 5 (Reuters) - Surface Oncology Inc SURF.O :
* SURFACE ONCOLOGY ANNOUNCES FIRST PATIENT DOSED IN A PHASE
1/2
STUDY EVALUATING SRF114, A POTENTIAL BEST-IN-CLASS ANTI-CCR8
ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS
* SURFACE ONCOLOGY INC - INITIAL CLINICAL DATA ANTICIPATED
IN 2024
Source text for Eikon: ID:nGNXbS8Gg6
Further company coverage: SURF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Surface Oncology
See all newsBrief: Surface Oncology Says Anticipates Will Have Net Cash Of $20 Million To $25 Million At The Closing Of The Proposed Mergers
Surface Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Surface Oncology, Inc. Q2 Net Income USD -28.2 Mln
Surface Oncology Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: ADAR1 Partners Reports 5.24% Passive Stake In Surface Oncology Inc As Of July 10 - SEC Filing